论文部分内容阅读
糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病最常见、最严重的微血管并发症之一。近年来,随着我国糖尿病发病率不断增高,DR致盲的人数也呈逐年上趋势,而糖尿病人群中合并DR者约30%~50%,其中25%有明显视力障碍,生存质量和生活水平严重下降~([1])。目前对DR的防治尚无特效药物。根据疾病发展的不同阶段和严重程度,对于重度非增殖性(NPDR)和增殖性(PDR)的DR进行激光光凝治疗能有效降低致盲风险。然而,作为一种有创
Diabetic retinopathy (DR) is one of the most common and serious microvascular complications of diabetes. In recent years, with the increasing incidence of diabetes in our country, the number of DR blindness also showed a trend of year by year. However, about 30% -50% of DR patients with diabetes mellitus, 25% of whom have obvious visual impairment, quality of life and living standard Serious decline ~ ([1]). At present there is no effective drug for the prevention and treatment of DR. Depending on the stage and severity of the disease, laser photocoagulation of severely nonproliferative (NPDR) and proliferative (PDR) DR can effectively reduce the risk of blindness. However, as a kind of invasive